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Risk factors of progressive community-acquired pneumonia 37admission. Demographic, clinical, and laboratory variables, diagnosis, antimicrobial therapy,
and pathogens were compared.
Results: Four hundred and two children were included and 57 (14.2%) had progressive pneu-
monia. Independent associated factors identified for the development of progressive disease,
by multivariate logistic regression analysis, included the following, age < 2 years, pleural effu-
sion as admission diagnosis, Hb < 10 g/dL, WBC count > 17,500/mL, tachypnea, and duration to
defervescence > 3 days. Streptococcus pneumoniae was the main etiology for progressive
pneumonia (57.9%). There was no difference in choice of initial parenteral antibiotics between
groups of progressive and non-progressive pneumococcal pneumonia.
Conclusion: We found six clinical factors for predicting progressive pneumonia. Further evalu-
ation should be performed in hospitalized pneumonic children with persistent fever not re-
sponding to therapy within 72 hours. The initial parenteral antibiotics were not related to
the progression of pneumococcal pneumonia.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The mortality rate of pneumonia has fallen since effective
antibiotic treatment and vaccines for the two most com-
mon pneumonia-causing pathogens, Haemophilus influen-
zae type b and Streptococcus pneumoniae, became
available.1,2 Despite a drop in overall mortality cases,
pneumonia is still the leading killer and cause of morbidity
in children, especially among those < 5 years old.3 Com-
plications of pneumonia occur even when children are
hospitalized and receive treatment. Pulmonary complica-
tions of pneumonia include pleural or parapneumonic
effusion, pneumothorax, acute respiratory distress, empy-
ema, necrotizing pneumonia, bronchopleural fistula,
pneumatocele formation, and lung abscess. These compli-
cations lead to prolonged hospitalization, surgery, and
irreversible sequelae in children.
How long should the physician wait prior to evaluating the
failure of treatment? When should the physician take the
next step to prevent the complications of pneumonia?
Although current treatment guidelines give some suggestions
for managing community-acquired pneumonia (CAP),4 there
is very little information about the risk factors for progressive
pneumonia in children. Pneumonia has complex and varying
causes, clinical presentation, and severity. Given the vari-
ability in the range of clinical response and radiographic
resolution, it remains controversial as to when to alter
initially empirical therapy for progressive pneumonia.
The purpose of our study was to compare the clinical
characteristics and laboratory parameters of children hos-
pitalized with progressive pneumonia, with those of children
with non-progressive pneumonia and to identify risk factors
for a progressive course. We also wanted to determine when
the physician should take the next step to prevent compli-
cations, if the patient does not response well to therapy.
Methods
Study population
We prospectively enrolled pediatric patients, aged from 6
weeks to 18 years, who were admitted to the pediatricdepartments of seven medical centers in Taiwan, from
January 2010 to August 2011, with the diagnosis of CAP.
Children were excluded if they had proven immunodefi-
ciency or immunosuppression in previous medical records.
The patients were evaluated at admission and after 1 day to
3 weeks, at which time demographic and clinical data were
collected uniformly and laboratory specimens were
obtained.Definition
For purposes of this study, the diagnosis of pneumonia was
based on radiographic findings. The severity of pneumonia
was categorized according to the radiological confirmation
in order of segmental pneumonia, lobar pneumonia, pleural
effusion, empyema, necrotizing pneumonia, pneumato-
cele, and lung abscess. Non-progressive pneumonia was
defined by discharge diagnosis being consistent with
admission. By contrast, progressive pneumonia was defined
by the deterioration of discharge diagnosis as compared to
admission.Study variables
Medical profiles were recorded for age, sex, underlying
disease, presenting signs, symptoms, physical examination
findings, laboratory data, chest radiography findings,
duration of fever prior to hospitalization, time to defer-
vescence, duration of hospitalization, antimicrobial ther-
apy, pathogens, and diagnoses on admission and discharge.
Laboratory data including hemoglobin (Hb), white blood
cell (WBC) and platelet count, C-reactive protein (CRP),
blood urea nitrogen, creatinine, aspartate aminotrans-
ferase, alanine aminotransferase, albumin, and Thomsen-
Friedenreich antigen (T-antigen) were collected and
analyzed. T-antigen was tested using the peanut (Arachis
hypogaea) lectin agglutination method.
Pathogens were surveyed by: bacterial culture from
blood, pleural effusion, and sputum specimen, and rapid
antigen assays for S. pneumoniae, H. influenzae type b,
respiratory syncytial virus, and influenza virus; throat or
38 C.-Y. Huang et al.nasopharyngeal viral culture; and serology studies for My-
coplasma pneumoniae.
The diagnostic criteria for definite pneumococcal pneu-
monia infection included: (1) isolation of S. pneumoniae from
blood and/or sterile body site; (2) S. pneumoniae identified
from sputum culture plus positive urine pneumococcal anti-
gen; and (3) positive pneumococcal antigen in pleural effu-
sion. The probable diagnostic criteria were positive urine
pneumococcal antigen or S. pneumoniae identified from
sputum culture. M. pneumoniae enzyme-linked immunoas-
says were performed. The assay was considered positive
if the immunoglobulin M (IgM) was positive or there was a
4-fold rise in immunoglobulin G (IgG) titer.
Statistical analyses
The results are presented as mean  standard deviation for
continuous variables, and percentages for category vari-
ables. Differences between progressive and non-
progressive pneumonia groups were calculated using the
Student t test for continuous variables and Chi-square test
for categorical variables. All variables that were statisti-
cally significant with p < 0.05 were included in a multi-
variable mode to identify independent predictors for
progressive pneumonia. All probabilities were 2-tailed.
Odds ratios and their 95% confidence intervals were also
determined. All analyses used the SPSS statistical package
(SPSS Inc., Chicago, IL, USA).
Results
A total of 410 children hospitalized with CAP were enrolled
from January 1, 2010 to August 31, 2011. The diagnoses of
the patients included segmental pneumonia (123), lobar
pneumonia (201), pleural effusion (65), empyema (13), and
necrotizing pneumonia (8). The diagnoses at admission and
discharge are listed in Table 1. Eight patients with necro-
tizing pneumonia at admission were excluded for further
analysis because they reached the greatest severity ac-
cording to our definition. The other 402 children were
classified into two groups. A total of 57 (14.2%) children met
the criteria of progressive pneumonia and 345(85.8%) chil-
dren had non-progressive pneumonia.
Selected clinical characteristics of the patients with
progressive versus non-progressive pneumonia are listed in
Table 2. Hospitalized children with progressive pneumoniaTable 1 The discrepancies between admission and discharge dia
acquired pneumonia
Admission diagnosis (Patient No.)
Segmental (111) Lobar
Segmental (123) 111 6
Lobar (201) 181
Effusion (65)
Empyema (13)
Necrotizing (8)
Effusion Z pleural effusion; lobar Z lobar pneumonia; necrotizing Zwere younger (average age Z 4.0 years vs. 5.7 years;
p < 0.001) and more likely to be < 2 years old (26.3% vs.
8.6%, p Z 0.005), and have tachypnea (p < 0.001) and
abdominal pain (p Z 0 .001) on presentation. There were
no differences with regard to the male to female ratio,
numbers of siblings, background disease, hospitalization
history for respiratory tract disease, vaccination with hep-
tavalent pneumococcal conjugate vaccine (PCV7), or
annual influenza vaccine. About one third of children in
both groups received PCV7.
Patients with progressive pneumonia were admitted
under the following diagnoses: 43.1% with pleural effusion,
35.1% with lobar pneumonia, 21% with segmental pneu-
monia, and 1.8% with empyema. A higher percentage of
children with progressive pneumonia had pleural effusion
as an admission diagnosis as compared to children with non-
progressive pneumonia (43.1% vs. 11.9%, p < 0.001).
The mean duration of fever prior to admission was 5.2
days for the progressive patients versus 4.5 days for the
non-progressive patients (p < 0.001). The mean time to
defervescence after admission for patients with progressive
pneumonia was 6.4 days (median Z 5 days; range Z 0e18
days) versus 2.3 days (median Z 2 days; range Z 0e14
days) for patients with non-progressive pneumonia
(p < 0.001). Seventy-three percent of patients in the pro-
gressive group continued to have a fever by Day 4 of hos-
pitalization versus 23.2% in the non-progressive group
(p < 0.001). Children with the progressive clinical course
had a longer duration of hospitalization (mean 16.2 days vs.
7.5 days, p < 0.001).
Children with progressive disease had a lower Hb count
(9.5 g/dL vs. 11.4 g/dL, p < 0.001), a higher WBC count
(21.3  103/mL vs. 14.5  103/mL, p < 0.001), higher CRP
(24.2 mg/dL vs.14.3 mg/dL, p < 0.001), higher platelet
count (519.8  103/mL vs. 380.8  103/mL, p Z 0.001),
lower albumin (2.6 g/dL vs. 3.7 g/dL, p < 0.001), and a
positive rate for T-antigen (50% vs. 0 %, p < 0.001).
On multivariate logistic regression, age < 2 years,
pleural effusion as admission diagnosis, Hb < 10 g/dL, WBC
count > 17.5  103/mL, tachypnea, and days to deferves-
cence > 3 were identified as independent predictors of the
subsequent development of progressive disease (Table 3).
An etiologic diagnosis was established in 50 (87.7%)
progressive and 169 (48.9%) non-progressive pneumonia
patients (p < 0 .001). The most frequently identified
pathogens in progressive and non-progressive groups
were S. pneumoniae (57.9% and 28.4%, p < 0.001),gnosis of the hospitalized pediatric patients with community-
Discharge diagnosis (Patient No.)
(187) Effusion (55) Empyema (44) Necrotizing (13)
6
8 10 2
41 22 2
12 1
8
necrotizing pneumonia; segmental Z segmental pneumonia.
Table 2 Characteristics of children with progressive and non-progressive community-acquired pneumonia during
hospitalization
Characteristics Mean  SD pa
Progressive
(n Z 57)
Non-progressive
(n Z 345)
Demographic
Age (year; mean, range) 4.0  0.6 5.7  0.4 < 0.001
Age (year; median, range) 3.7 (0.4e14.7) 4.7 (0.3e17.6)
> 2 y 26.3 8.6 0.005
 2 ye5 y 59.6 59.1 0.894
 6 y 14.0 32.3 0.07
Male/female ratio 0.9 1.0 0.886
Hospitalization history for respiratory
tract disease
21.1 25.7 0.512
Previous PCV7 vaccination 33.3 31.8 0.879
Annual influenza vaccination 28.1 39.7 0.106
Admission radiographic findings
Segmental pneumonia 21.0 32.2 0.12
Lobar pneumonia 35.1 52.4 0.022
Pleural effusion 43.1 11.9 < 0.001
Empyema 1.8 3.5 0.703
Clinical presentations
Tachypnea 80.7 31.9 < 0.001
Abdominal pain 45.8 15.9 0.001
Fever prior to admission (days) 5.2  0.7 4.5  0.3 < 0.001
Duration to defervescence (days) 6.4  1.2 2.3  0.3 < 0.001
Duration of hospitalization (days) 16.2  2.8 7.5  0.7 < 0.001
Hematological findings
Lowest Hb (g/dL) 9.5  0.5 11.4  0.2 < 0.001
Highest WBC count (103/mL) 21.3  3.1 14.5  0.9 < 0.001
Highest CRP (mg/dL) 24.2  3.2 14.3  1.4 < 0.001
Highest platelet count (103/mL) 519.8  78.4 380.8  20.0 0.001
Lowest albumin (g/dL) 2.6  0.3 (n Z 22) 3.7  0.2 (n Z 33) < 0.001
Positive T-antigen 50.0 (10/20) 0.0 (0/27) < 0.001
a Presence of progressive pneumonia versus non-progressive pneumonia.
Data are presented as % unless otherwise indicated.
CRP Z C-reactive protein; Hb Z hemoglobin; PCV7 Z 7-valent pneumococcal conjugate vaccine; T-antigen Z Thomsen-Freidenreich
antigen; WBC Z white blood cell.
Risk factors of progressive community-acquired pneumonia 39M. pneumoniae (12.3% and 11.4%), and viral pneumonia
(8.8% and 9.3%). The pathogens detected in children with
progressive pneumonia are shown in Fig. 1. Pneumococcal
pneumonia was found in 33 children with progressive
pneumonia. Ten of these were a definite and 23 were a
probable diagnosis.Table 3 Independent predictors of the progressive community-
Clinical feature Patient No. Progressive (%
Age < 2 y 44 22.8
Pleural effusion as admission
diagnosis
65 43.1
Tachypnea 156 80.7
Hb < 10 g/dL 76 56.1
WBC > 17500/mL 129 57.9
Days to defervescence > 3 days 122 73.7
AOR Z adjusted odds ratio; CI Z confidence interval; Hb Z hemogloA comparison of initial antibiotic treatment for children
with pneumococcal pneumonia is shown in Table 4. Ninety-
three point one percent of children with progressive
pneumonia started parenteral antibiotics at admission
versus 92.9% of children with non-progressive pneumonia
(p Z 1.0). There was no statistically significant differenceacquired pneumonia by multivariate model
) Non-progressive (%) AOR (95% CI) p
8.9 3.48 (1.26e10) 0.02
11.9 14.10 (1.37e145.2) 0.03
31.9 4.24 (1.77e10.16) < 0.001
12.7 2.38 (1.00e5.67) 0.05
27.8 2.42 (1.08e5.45) 0.03
23.2 3.04 (1.30e7.130) 0.01
bin; WBC Z white blood cell.
Figure 1. Etiology of progressive community-acquired pneumonia.
40 C.-Y. Huang et al.in the choice of initial parenteral antibiotics between the
two groups.Discussion
This study identifies key features that can determine chil-
dren at risk for the development of progressive pneumonia.
The initial severity of CAP, in our study, presented with
pleural effusion as an admission diagnosis, is an important
factor that determines the outcome of the disease and may
predict which patients are more likely to fail with regards
to empirical treatment, or to have progressive pneumonia.
Tachypnea is also a clue for progressive pneumonia.
Guidelines developed by the World Health Organization for
the clinical diagnosis of pneumonia in developing countries,
highlight tachypnea and retractions as the two best in-
dicators of lower respiratory tract infection (LRTI).5 Palafox
et al6 observed that, in children younger than 5 years of
age, of all the clinical signs, tachypnea had the highest
sensitivity (74%) and specificity (67%) for radiologically
confirmed pneumonia, but it was less sensitive and specific
in early disease. This indicates that tachypnea is not only a
sign of LRTI, but also a sign to predict acute respiratory
distress, which is one of the pulmonary complications of
CAP.Table 4 Comparison of initial antibiotics for pneumococcal pne
Antibiotics Progr
Parenteral antibiotics 93.9
1st line antibioticsa  macrolideb 39.4
3rd cephalosporinc and/or glycopeptided  macrolide 54.5
a Aq. Penicillin, ampicillin, cefuroxime, or augmentin.
b Azithromycin, erythromycin, or roxithromycin.
c Cefotaxime or ceftriaxone.
d Vancomycin or Targocid.
Data are presented as %.We show that children with progressive pneumonia have
a greater degree of inflammation, as evidenced by that fact
that WBC > 17.5  103/mL is an independent risk factor of
progressive pneumonia. Higher CRP and platelet counts are
also associated with the progressive disease in our study,
which also reflects a more severe inflammatory response.
Similar to other studies, anemia was shown to be a risk
factor for developing invasive pneumococcal disease,
including pneumonia, and is a marker for increased
morbidity and mortality.7,8 Children with progressive
pneumonia have a higher rate of hypoalbuminemia and
positive T-antigen in our study. Hypoalbuminemia is well
recognized in severe CAP, as well as being associated with
the parapneumonic effusion and empyema. Large effusions
are associated with low serum albumin, which might be
explained in part by a shift from blood to pleural fluid.9 T-
antigen presented on erythrocytes, platelets, and glomeruli
is exposed by an enzyme produced by the pneumococcal
organism. T-antigen positive implies that the patient
may have pneumonia caused by S. pneumoniae.10e12 How-
ever, neither positive T-antigen, nor hypoalbuminemia, is
statistically different between progressive and non-
progressive pneumonia after multivariate logistic regres-
sion. This may be related to the reduced case numbers
(total 47 patients and 55 patients checked T-antigen and
albumin, respectively).umonia
essive (n Z 33) Non-progressive (n Z 98) p
92.9 >0.99
49.0 0.421
43.9 0.318
Risk factors of progressive community-acquired pneumonia 41Persistent fever of > 72 hours after admission is another
important clinical feature significantly associated with
hospitalized children having progressive pneumonia. Cur-
rent practice guidelines for the management of CAP showed
that for children whose condition deteriorates after initia-
tion of antimicrobial therapy, or who show no improvement
within 72 hours, further evaluation is needed.13 Follow-up
chest radiographs should be obtained in patients with
complicated pneumonia with worsening respiratory distress
of clinical instability, or in those with persistent fever that
is not responding to therapy over 48e72 hours.4 Our study
supports this advice, because 73.7% of children with pro-
gressive pneumonia had persistent fever over 72 hours after
admission. Repeating a chest radiograph should be consid-
ered to identify probable complications in such patients
and therapy must be reviewed.
Most of our patients hospitalized with CAP were aged
between 2 years and 5 years (59.1%) with a mean age of 4
years, which is similar to previous studies.14,15 However,
the rate of children < 2 years old in the progressive pneu-
monia group was significantly higher than in the non-
progressive group (26.3% vs. 8.6%, p Z 0.005). This is not
compatible with previous studies for complicated and un-
complicated pneumonia in hospitalized children.14e16 Tan
at al14 found that children hospitalized with complicated
pneumonia tended to be significantly older than those with
uncomplicated pneumonia (45 months vs. 27 months).
There could be several reasons for these differences. Most
of their studies focused on patients with pneumococcal
pneumonia, whereas ours included all etiologies, although
S. pneumoniae remained the major cause of progressive
pneumonia (57.9% in the progressive group; 60% in
children < 2 years old in the progressive pneumonia group).
The time span on our study was different from that of Tan
et al.14 Their study covered the time period from 1994 to
1999, during which there was a significant increase in the
proportion of their patients with complicated pneumonia
(from 22.6% to 53%). It is possible that during this period,
the distribution of pneumococcal serotypes may have
changed in favor of more virulent subtypes, or subtypes
with a propensity for different age groups. Another recent
study, conducted by Kunyoshi et al,17 supported our find-
ings by showing that the incidence of complicated pneu-
monia was higher in the 2nd year of life. In addition, a lower
rate of PCV7 vaccination (overall 32% in our study) and
genetic factors may explain the disparity in the epidemi-
ology of progressive pneumonia in Taiwan, compared to
Western countries.
The rate of etiologic diagnosis was higher in progressive
than non-progressive pneumonia (87.7% vs. 49.8%,
p < 0.001). This may be due to the fact that patients with
progressive disease have a longer length of stay or more
complicated disease; they may also receive more diagnostic
tests and have an increased rate of etiologic diagnosis. S.
pneumoniae remains the most frequently identified path-
ogen in children hospitalized with CAP, which is similar to a
previous study.18 In our study, bacteria accounted for 79%
of infections in children with progressive pneumonia, of
which 71% were caused by S. pneumoniae.
We further analyzed the initial choice of antimicrobial
therapy for pneumococcal pneumonia. Overall, 93.9% pa-
tients received parenteral antibiotics in the beginning andthere was no significant difference in the choice of initial
parenteral antibiotics between progressive and non-
progressive pneumonia patients (whether 1st line antibi-
otics or 3rd generation cephalosporins). The progression of
disease is not related to the initial parenteral antibiotics, as
most pediatricians choose antibiotics according to the
guidelines.4,13,19 Bacterial virulence or host factor is
likely to play a more important role in the progression of
the disease, as manifested by age < 2 years being an in-
dependent risk factor for progressive pneumonia in our
study.
Some potential limitations with regards to the present
study should be taken into account. As the sample size is
limited in relation to some parameters (albumin and T-an-
tigen), those factors that have a weak association with
progressive pneumonia might not have been detected.
Another potential limitation is that the preadmission
treatment was not available, so we could not evaluate the
effect of that on children with progressive pneumonia.
Finally, the susceptibility of antibiotics to isolated bacteria
was not recorded and related detailed analysis was not
done.
In conclusion, we identified six independent risk factors
for progressive pneumonia including: age < 2 years, pleural
effusion as admission diagnosis, tachypnea, Hb < 10 g/dL,
WBC count > 17.5  103/mL, and duration to defervescence
> 3 days. If the patient has fever for more than 72 hours
without evidence of clinical improvement after initial
treatment, further evaluation or a follow-up chest radio-
graph is needed to confirm cases of progressive pneumonia.
The initial choice of parenteral antibiotics was not related
to the progression of pneumococcal pneumonia.Conflicts of interest
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